Lartruvo fails confirmatory study; Lilly suspending promotion

Eli Lilly and Co. (NYSE:LLY) said on Jan. 18 that it will suspend promotion of Lartruvo olaratumab after it missed the primary endpoints of the Phase III ANNOUNCE trial to treat advanced or metastatic soft tissue sarcoma. The trial was designed as a confirmatory study of the drug, which has accelerated approval from FDA and conditional approval from EMA in the indication.

Lilly said it will work with regulators to determine appropriate next steps for the drug. It said patients already receiving Lartruvo may continue to receive the drug, but the study's results do not support starting treatment in new soft tissue sarcoma patients outside of a clinical trial...